Evidence map›Paper›PMID 34970495›Full record

SynthesisFrontiers in oncology2021

Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis.

Peng Xiang, Zhen Du, Yongxiu Hao, Di Guan, Dan Liu, Wei Yan, Mingdong Wang, Yutong Liu, Hao Ping

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Bladder cancer risk factors: a comprehensive umbrella review of meta-analyses.International journal of surgery (London, England) · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Bladder cancer.Nature reviews. Disease primers · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Peng XiangDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Zhen DuDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Yongxiu HaoDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Di GuanDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Dan LiuDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Wei YanDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Mingdong WangDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Yutong LiuDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Hao PingDepartment of Urology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Beijing Tongren Hospital · CNBeihang University · CNCapital Medical University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to summarize the existing evidence and develop a comprehensive systematic review of the impact of androgen suppression therapy (AST) on the incidence or clinical outcomes of bladder cancer.

methodsWe systematically searched the PubMed and Embase databases from inception to June 20, 2021 to identify all observational studies examining the incidence or clinical outcomes of bladder cancer in patients who received AST. AST is defined as the use of 5-alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT).

resultsA total of 18 observational studies were included. Our results showed that AST was not significantly associated with a reduced risk of BCa incidence (OR: 0.92, 95% CI: 0.68-1.24) compared with the lack of AST. The subgroup analysis revealed that finasteride use was significantly associated with a reduction in the risk of BCa incidence (OR: 0.75, 95% CI: 0.64-0.88). Recurrence-free survival (RFS) was improved among AST users compared with nonusers (HR: 0.68, 95% CI: 0.48-0.95), while no significant difference between AST users versus nonusers was identified for cancer-specific survival (CSS), overall survival (OS) or progression-free survival (PFS).

conclusionCurrent evidence indicates that therapy with finasteride may represent a potential strategy aimed at reducing BCa incidence. Moreover, AST has a beneficial effect on the recurrence of bladder cancer. Further well-designed randomized trials or cohort studies with better characterized study populations are needed to validate our preliminary findings. SYSTEMATIC REVIEW REGISTRATION: International Prospective Register of Systematic Reviews database [https://www.crd.york.ac.uk/PROSPERO/], identifier CRD42021261685.

Indexed as

androgen suppression therapybladder cancerincidencemeta-analysisrecurrence

Identifiers

PMID34970495
PMCPMC8712679
OpenAlexW4200044835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.